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A B S T R A C T
Background: Long-term outcomes of very late stent thrombosis (VLST) after implantation of drug-eluting
stents (DES) are still unclear. The aim was to evaluate the long-term outcomes after VLST of DES, and to
analyze the related factors of long-term outcomes in these patients.
Methods: From January 2006 to February 2013, patients with angiographically deﬁned VLST were
studied. The clinical characteristics, angiography and interventional data, and anti-platelet therapy
protocols were analyzed. The patients were divided into two groups according to the occurrence of major
adverse cardiac events (MACE) during follow-up. The clinical and interventional data between the two
groups were compared.
Results: Sixty-two patients were enrolled consisting of 55 males and 7 females with an average age of
58.6  10.2 (41–82) years. The mean time from ﬁrst implantation of DES to occurrence of VLST was
38.7  18.1 (12.5–84) months. One patient died in hospital. Sixty-one patients survived to discharge, and
MACE occurred in 17 patients after a median follow-up of 32.1  19.1 (median: 44, range 5–88) months. The
total MACE rate was 29.0% (18/62), and Kaplan–Meier survival analysis showed the estimated MACE-free
survival was 45.1%. The rate of implantation of an additional ﬁrst-generation DES during the ﬁrst VLST in the
group with events was higher (44.4% vs.11.4%, respectively, p = 0.007). The percentage of continuous dual
antiplatelet therapy (DAPT) at the longest available follow-up was higher in the event-free group (27.8% vs.
75.0%, respectively, p = 0.001). Multivariable Cox regression analysis revealed that the only independent
predictors for freedom of MACE during long-term follow-up was continuous DAPT at the longest available
follow-up [hazard ratio (HR) = 0.30, 95% CI: 0.09–0.97, p = 0.04].
Conclusions: Long-term outcomes after VLST were unfavorable. Implantation of an additional ﬁrst-
generation DES might be avoided, and DAPT should be continued.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Compared with bare metal stents (BMS), drug-eluting stents
(DES) can signiﬁcantly reduce the rates of in-stent restenosis (ISR)
and target vessel revascularization (TVR) [1,2]. DES are used widely
during clinical practice [3]. However, safety concerns regarding
stent thrombosis (ST), especially late thrombosis, have arisen
[4–6]. Although the rate of very late stent thrombosis (VLST)
increased during clinical practice, there were few studies* Corresponding author. Tel.: +86 13701057123/10 85231170; fax: +86 10 65951064.
E-mail address: yxc6229@sina.com (X. Yang).
http://dx.doi.org/10.1016/j.jjcc.2014.11.014
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsconducted regarding the long-term follow-up of VLST. Long-term
outcomes of VLST after implantation of DES are still unclear and
optimal strategies of revascularization and anti-platelet therapy




From January 2006 to February 2013, 3945 patients who
received emergency coronary angiographies were evaluated. The
patients with angiographically deﬁned VLST were enrolled. reserved.
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Academic Research Consortium (ARC) deﬁnition [7]. VLST was
deﬁned according to the timing of the ST event occurring more
than one year after the index procedure. The clinical character-
istics, angiography and interventional data, and anti-platelet
therapy protocols were analyzed.
Deﬁnition
Major adverse cardiac events (MACE) included myocardial
infarction (MI), recurrence of ST, TVR, and death in all causes. The
diagnosis of MI required detection of a rise and/or fall of cardiac
biomarker values (cardiac troponin) with symptoms of ischemia
and electrocardiographic changes [8]. Recurrent ST was deﬁned
according to the ARC deﬁnition [7]. TVR was deﬁned as ischemia-
driven percutaneous coronary intervention (PCI) performed in the
same vessel as the index PCI with or without implantation of a
stent or coronary artery bypass grafting (CABG). Deaths were
classiﬁed as cardiac or non-cardiac. Dual antiplatelet therapy
(DAPT) was deﬁned as antiplatelet therapy with 100 mg/day
aspirin and 75 mg/day clopidogrel. First-generation DES included
sirolimus-eluting (SES) or paclitaxel-eluting stents (PES) with
durable polymers. New-generation DES included bioabsorbable
polymer-based DES, polymer-free DES, zotarolimus-eluting stents
(ZES), and everolimus-eluting stents (EES) [9–11].
Clinical follow-up and grouping
Clinical follow-up was done from hospital records and
telephone interviews with the patients or their relatives. According
to occurrence of MACE during follow-up, the patients were divided
into groups: with events or event free. The clinical and
interventional data between the two groups were compared.
Statistical analysis
SPSS Statistics 17.0 software (Chicago, IL, USA) was used.
Measurement data are expressed as mean  standard deviation;
enumeration data are expressed as percentages, and analyzed by
t-test and x2 test (exact test if necessary), respectively. A Kaplan–
Meier survival analysis was used to estimate MACE-free survival.
Predictors of MACE were assessed with Cox regression analysis. A
two-sided p-value of less than 0.05 indicated statistical signiﬁcance.Table 1
Clinical characteristics of patients.
Over all (n = 62
Male sex, n (%) 55 (88.7) 
Age, years (mean  SD) 58.6  10.2 
Detection duration to occurrence of VLST, m 38.7  18.1 
Region of MI (ST segment elevation in anterior wall), n (%) 46 (74.2) 
Killip class of 1–2, n (%) 58 (93.5) 
Risk factors
Hypertension, n (%) 33 (53.2) 
Diabetes mellitus, n (%) 17 (27.4) 
Hyperlipidemia, n (%) 30 (48.4) 
Smoking, n (%) 45 (72.6) 
Medical treatment
Statins, n (%) 56 (90.3) 
ACEI/ARB, n (%) 23 (37.1) 
B-blocker, n (%) 45 (72.6) 
Insulin, n (%) 5 (8.1) 
LVEF, % 55.8  12.0 
Peak value of cardiac troponin I, ng/ml 74.8  72.8 
VLST, very late stent thrombosis; MI, myocardial infarction; ACEI/ARB, angiotensin-c
ejection fraction.Results
Sixty-two patients met the deﬁnition of deﬁnite VLST. There
were 55 males, and the average age was 58.6  10.2 (41–82) years.
The mean time from ﬁrst implantation of DES to occurrence of VLST
was 38.7  18.1 (12.5–84) months. Clinical presentation of VLST was
acute MI in all patients, mostly with ST segment elevation in the
anterior wall (46/62, 74.2%), nine in the inferior wall, two in the
lateral wall, and ﬁve with non-ST-elevation MI. There were
41 patients, 17 patients, and 2 patients with Killip class 1, 2, and
3, respectively. There were two patients with cardiogenic shock
(Killip class 4). When VLST occurred, aspirin was taken in 41 patients,
clopidogrel in 1 patient, and DAPT in 5 patients. No antiplatelet agents
were taken in the rest of the 15 patients (Table 1).
During the initial PCI procedure, ﬁrst-generation DES was
implanted in 54 patients, including SESs with durable polymer in
52 patients, PES in 1 patient, and combined SES and PES in
1 patient. New-generation DES were implanted in six patients,
including bioabsorbable polymer-based SESs in three patients,
ZESs in two patients, and EES in one patient. The type of DES was
unclear in two patients who received the ﬁrst PCI in other
hospitals. According to the year of stent implantation and
description by the family, DES in these two patients could be
conﬁrmed as ﬁrst generation.
VLST occurred most frequently in the left anterior descending
artery (LAD, 47/62, 75.8%), 1 in the left main artery, 3 in the
circumﬂex, and 11 in the right coronary artery. Intra-aortic balloon
pumps were implanted in seven patients. Due to health insurance
issues, only three patients received intra-vascular ultrasound
(IVUS) and two patients received optical coherence tomography
(OCT) examination. Sixty patients received emergency PCI after
angiography. Forty-three patients received additional stents re-
implanted, had balloon angioplasty and/or thrombosis aspiration
without stent implantation was performed in 14 patients,
2 patients received selective CABG after balloon angioplasty, and
recanalization failed in 1 patient. Following intravenous throm-
bolytic therapy in another hospital, one patient received medica-
tion therapy after emergency angiography which showed there
was ﬂow of thrombolysis in myocardial infarction (TIMI) class 3. In
the rest of the population, one patient received medication therapy
and emergency angiography showed there was ﬂow of TIMI class
3 with thrombosis which disappeared in selective repeat
angiography. In the 43 patients that received additional stent) With events (n = 18) Event free (n = 44) p
16 (88.9) 39 (88.6) 1.0
61.2  10.3 57.5  10.1 0.20
34.8  15.1 40.3  19.1 0.28
14 (77.8) 32 (72.7) 0.76
17 (94.4) 41 (93.2) 1.0
11 (61.1) 22 (50.0) 0.58
4 (22.2) 13 (29.5) 0.76
6 (33.3) 24 (54.5) 0.17
11 (61.1) 34 (77.3) 0.22
15 (83.3) 41 (93.2) 0.34
6 (33.3) 17 (38.6) 0.78
12 (66.7) 33 (75.0) 0.54
2 (11.1) 3 (6.8) 0.62
56.4  11.1 55.5  12.5 0.80
72.0  70.5 76.0  74.6 0.84
onverting enzyme inhibitor/angiotensin receptor blocker; LVEF, left ventricular
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polymer-based SESs in 11 patients, bioabsorbable polymer-based
SES and graft stent in 1 patient, polymer-free PES in 4 patients, ZES
in 9 patients, and EES in 3 patients. The remainder of the
13 patients received ﬁrst-generation DES implantation (SESs with
durable polymer in 7 and PESs with durable polymer in 6, Table 2).
In the patients who received additional stent implantation, 90.7%
of them received post-dilatation.
In hospital, one 78-year-old female patient died of intracerebral
hemorrhage 4 days after the second PCI. Sixty-one patients
survived to discharge, and MACE occurred in 17 patients after a
median follow-up of 32.1  19.1 (median: 44, range 5–88) months.
MI due to non-target vessel was detected in four patients. VLST
reoccurred in seven patients. The second VLST occurred in six
patients, and emergency PCI was performed in four patients, CABG in
one patient, and medication only therapy in one patient after OCT
examination. Two more VLST attacks occurred in one patient, and
CABG was ﬁnally performed. Three patients received PCI again
because of ISR, and another three patients died. The total MACE rate
was 29.0% (18/62), and Kaplan–Meier survival analysis showed that
the estimated MACE-free survival during follow-up was 45.1% (Fig. 1).
Three patients who received CABG took aspirin only after
surgery. At the longest available follow-up, 38 (61.3%) patients
took continuous DAPT. There was one patient who took aspirin and
warfarin because of thrombosis in the left ventricle. In the rest of
the 19 patients, clopidogrel was stopped 1–2 years after VLST, and
only an aspirin regimen remained.
According to occurrence of MACE during follow-up, the patients
were divided into two groups, one group with events and one
event-free group. Baseline clinical characteristic and angiography
data were compared between the two groups and no signiﬁcant
differences were found (Tables 1 and 2). In addition, no signiﬁcant
differences were observed in the rate of implantation of an
additional stent between the two groups. However, the rate of
implantation of additional ﬁrst-generation DES during the ﬁrst
VLST in the event group was higher than in the event-free group
(44.4% vs.11.4%, respectively, p = 0.007). At the longest availableTable 2
Angiographic and interventional characteristics of the patients.
Over all (n = 62) 
Initial lesion and procedure characteristics
Emergency procedure, n (%) 21 (33.9) 
Target vessel (LAD), n (%) 47 (75.8) 
ISR, n (%) (n = 60) 1 (1.7) 
CTO, n (%) (n = 60) 2 (3.3) 
Two stents strategy for bifurcation, n (%) 3 (4.8) 
No. of stents 1.37  0.66 
1st generation DES implanted during 1st PCI, n (%) 54 (87.1) 
Stent diameter, mm (mean  SD, n = 60) 3.06  0.36 
Total stent length, mm (mean  SD, n = 60) 33.5  20.0 
Post-inﬂation, n (%) (n = 60) 49 (81.7) 
Max. inﬂation pressure, atm (mean  SD, n = 60) 15.6  2.71 
Lesion and procedure characteristics during VLST
Non-infarct-related artery with stenosis >50%, n (%) 52 (83.9) 
With LM disease, n (%) 5 (8.1) 
Self-recanalization of IRA (TIMI class 2–3), n (%) 9 (14.5%) 
Collateral circulation (Rentrop class 2–3), n (%) 14 (22.6) 
Thrombosis aspiration, n (%) 12 (19.4) 
Final ﬂow (TIMI class 3) 58 (93.5) 
Additional stent implantation, n (%) 43 (69.4) 
Re-implantation of 1st generation DES, n (%) 13 (19.4) 
No. of stents (n = 43) 1.51  0.70 
Additional stent diameter, mm (mean  SD, n = 43) 3.07  0.34 
Additional total stent length, mm (mean  SD, n = 43) 39.5  17.9 
Post-inﬂation, n (%) (n = 43) 39 (90.7) 
Max. inﬂation pressure, atm (mean  SD, n = 43) 18.4  3.21 
LAD, left anterior descending artery; ISR, in-stent restenosis; CTO, chronic total occlus
late stent thrombosis; LM, left main artery; IRA, infarct-related artery; TIMI, thrombfollow-up, the percentage of continuous DAPT was higher in the
event-free group (27.8% vs. 75.0%, respectively, p = 0.001).
Implantation of additional ﬁrst-generation DES (HR: 2.69,
p = 0.04) and continuous DAPT (HR: 0.25, p = 0.01) were detected
as predictors for freedom of MACE by univariate Cox analysis
(Table 3). Then, multivariable Cox regression analysis revealed that
the only independent predictors for freedom from MACE during
long-term follow-up was continuous DAPT at the longest available
follow-up (HR: 0.30, p = 0.04) (Table 3). The estimated MACE-free
survival between patients with or without DAPT was 85.0% and
11.4%, respectively (log rank, p = 0.01) (Fig. 2).
Discussion
Long-term safety of DES has been an issue of concern in clinical
practice. One study showed that increased rates of VLST were
found for both SES (0.6% vs. 0%, p = 0.025) and PES (0.7% vs. 0.2%,
p = 0.028) compared with BMS [5]. The risk factors and mecha-
nisms of VLST in DES might be different from early ST [12]. After
comparing the long-term outcome of early, late, and very late ST,
and reviewing the related literature, Kubo et al. concluded that
‘‘VLST was not related to lesion severity in index PCI’’ and the
lesions related to VLST occurrence could be less complicated than
those related to early ST and late ST [13]. In the early phase,
procedural factors are most likely responsible for ST, such as under
expansion and dissection at the stent edge [12]. However, delayed
and incomplete endothelialization caused by anti-proliferation
agents and localized hypersensitivity of durable polymers might be
the main reason for VLST [12,14]. Recently, neoatherosclerosis was
also reported to be a common mechanism of VLST [15].
Long-term outcomes of VLST after implantation of DES are still
unclear. Previous studies about ST enrolled patients with ST in BMS
and patients with acute, subacute, and late ST. There were few
studies speciﬁcally focused on VLST following DES, and in the few
studies conducted, few patients were enrolled. In one study,
116 patients with angiographically deﬁned ST after DES implanta-
tion were enrolled, but there were only 13 (12.2%) VLST patientsWith events (n = 18) Event free (n = 44) p
8 (44.4) 13 (29.5) 0.38
15 (83.3) 32 (72.7) 0.52
0 (0) 1 (2.4) 1.0
1 (5.6) 1 (2.4) 0.51
2 (11.1) 1 (2.3) 0.20
1.39  0.61 1.36  0.69 0.89
16 (88.9) 38 (86.4) 1.0
2.98  0.24 3.09  0.40 0.30
32.9  20.1 33.7  20.2 0.90
14 (77.8) 35 (83.3) 0.72
15.1  2.49 15.8  2.80 0.38
17 (94.4) 35 (79.5) 0.26
1 (5.6) 4 (9.1) 1.0
3 (16.7) 6 (13.6) 0.71
3 (16.7) 11 (25.0) 0.74
3 (16.7) 9 (20.5) 1.0
17 (94.4) 41 (93.2) 1.0
13 (72.2) 30 (68.2) 1.0
8 (44.4) 5 (11.4) 0.007
1.38  0.77 1.57  0.68 0.44
3.14  0.33 3.05  0.34 0.39
35.3  14.4 41.4  19.1 0.31
12 (92.3) 27 (90.0) 1.0
18.2  2.23 18.5  3.59 0.77
ion; DES, drug-eluting stent; PCI, percutaneous coronary intervention; VLST, very
olysis in myocardial infarction.
Fig. 1. Kaplan–Meier cumulative major adverse cardiac events (MACE)-free survival during follow-up.
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including only 23 VLST patients after DES implantation [17]. Nine-
teen patients with VLST after DES were enrolled in another study
sponsored by Kim et al., and no further study could be performed
because of the small enrollment numbers [18].
Sixty-two patients with angiographically deﬁned VLST after
DES were enrolled in our study. One patient died in the hospital.
Similarly, in Kim et al.’s study (0%) [18], in-hospital mortality in our
study (1.6%) was low. An additional previous study revealed higher
in-hospital mortality in patients with VLST [19]. In Armstrong
et al.’s study [19], in-hospital mortality of patients with VLST after
BMS and DES implantation was 3.6%. Compared with Armstrong
et al.’s study, there were more patients with low risk in our study,
which might be the reason for the difference in in-hospital
mortality. In our study, there were only two patients with
cardiogenic shock (3.2%). In Armstrong et al.’s study [19], 9.3%
of the patients had cardiogenic shock, and 6.2% of the patients had
cardiac arrest. In addition, only patients with angiographically
deﬁned VLST were enrolled in our study. Patients with ARC-
deﬁned probable or possible ST were not included, which might
cause ‘‘survivor bias’’ (e.g. patients with ST resulting in death
before repeat angiography were not captured).
However, the long-term outcomes of VLST after DES are
unfavorable. Seventeen events occurred during the long-term
follow-up of 32.1  19.1 months, and seven patients suffered from
another VLST. The total event occurrence was 29.0% (18/62), andTable 3
Cox regression analysis of the predictors for major adverse cardiac events.
HR 95% CI p
Univariable Cox regression analysis
Continuous DAPT 0.25 0.09–0.71 0.01
Implantation of additional 1st generation DES 2.69 1.05–6.86 0.04
Multivariable Cox regression analysis
Continuous DAPT 0.30 0.09–0.97 0.04
Implantation of additional 1st generation DES 1.45 0.50–4.22 0.50
HR, hazard ratio; CI, conﬁdence interval; DAPT, dual antiplatelet therapy; DES,
drug-eluting stent.Kaplan–Meier survival analysis showed that the estimated MACE-
free survival during follow-up was only 45.1%.
Optimal strategy of revascularization of VLST after DES is still
uncertain. Kim et al. observed that MACE was detected in patients
with balloon angioplasty only, so the authors assumed that placing
another stent might be helpful for these patients [18]. In another
study, a contradictory conclusion was made that the implantation
of an additional coronary stent was associated with unfavorable
outcomes [17]. However, there were only a few patients with VLST
after DES (5.3%) enrolled in this study [17]; therefore, the
conclusion might not ﬁt this particular subset of patients. In our
study, although no signiﬁcant difference was observed in the rate
of implantation of additional stents, the rate of implantation of an
additional ﬁrst generation of DES in the event group was higher.
The latest studies revealed that occurrence of ST after new DES
implantation was lower than that of the ﬁrst generation of DES
[10,20]. Although it is not yet conclusive, placing an additional
ﬁrst-generation DES might be avoided in this particular subset of
patients. Due to the small sample size, sub-group analysis about
different strategies of revascularization (balloon angioplasty only,
additional stent implantation, and CABG) and different types of
new-generation DES implantation (bioabsorbable polymer-based
DES, polymer-free DES, ZES, and EES) could not be made.
Duration of DAPT after DES implantation remains controversial
[21]. All patients in this study received DAPT for not less than
1 year after ﬁrst implantation of DES according to recommenda-
tions of the current guidelines [3,22], but ST occurred 1 year later.
When VLST occurred, there were 53% patients that took aspirin
alone in Kim et al.’s study [18]. In our study, aspirin alone was
taken by 41 patients, and no antiplatelet agent was taken in
15 patients. Large-scale clinical trials revealed that prolonged
DAPT was not signiﬁcantly more effective in reducing MACE, and it
might cause greater risk of hemorrhage [23,24]. Routine continu-
ation of DAPT beyond 12 months is not recommended by the
2011 American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines/Society for Cardio-
vascular Angiography and Interventions Guideline for PCI (class IIb
indications) [3]. However, no VLST patient was involved in the
above-mentioned trials [23,24], and the duration of DAPT was still
Fig. 2. Kaplan–Meier cumulative major adverse cardiac events (MACE)-free survival between patients with or without dual antiplatelet therapy (DAPT) during follow-up.
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continuous DAPT at the longest available follow-up was the only
independent predictor for the freedom from MACE. So, it should be
necessary to prolong the duration of DAPT in VLST patients,
especially in the patients who receive additional stent implantation.
There are several limitations that should be noted: (1) IVUS and
OCT might be helpful to show morphological changes of
thrombosis, endothelialization, and neoatherosclerosis intra-
DES. Due to insurance issues, only a few patients received IVUS
and OCT examination. (2) Because of the small sample size, the
power to identify predictors was reduced and sub-group analysis
(e.g. different strategy of revascularization) was not performed. A
multicenter registry study might be required. (3) This study was
observational, and a prospective, randomized, multicenter trial
might be required to determine the optimal strategy of revascu-
larization and antiplatelet therapy in these patients.
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